Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Incyte INCY expands AI drug discovery partnership with Genesis Molecular AI in a deal worth up to $1 billion-plus if all milestones across five initial targets…
Genesis will receive total upfront consideration of $120 million, which includes an $80 million upfront cash payment and a $40 million purchase of equity in…
Pharma roundup: Bristol Myers Squibb enters strategic agreement with Anthropic, Incyte and Genesis expand strategic collaboration. Incyte and Genesis Molecular…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Incyte expanded its collaboration with Genesis Molecular AI to accelerate development of small-molecule drugs using Genesis's GEMS platform, with a $120 million payment ($80 million cash plus $40 million equity) plus ongoing research funding and up to $232 million in milestones per program across at least five new targets. The expanded pact extends a February 2025 partnership and grants Incyte exclusive rights to resulting products.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Incyte Corporation / Genesis Molecular AI, Inc. (this deal) | 2026 | $1.0B | — |
| Incyte Corporation / MacroGenics, Inc. | 2017 | $900M | 69 |
| Incyte Corporation / Vega Therapeutics, Inc. | 2026 | $2.0B | 68 |
| Incyte Corporation / Merus N.V. | 2017 | $3.0B | 35 |
| Incyte Corporation / Escient Pharmaceuticals Inc. | 2024 | $750M | — |
| Incyte Corporation / Calithera Biosciences, Inc. | 2017 | $803M | — |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
← Browse all deals · How we score deals
More: 2026 deals · Incyte Corporation deals · Immunology deals